You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PHESGO

Showing 1 - 21 of 21
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial (Inavolisib, Phesgo, Placebo)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jun 7, 2023

Locally Advanced or Metastatic Breast Cancer Trial in Worldwide (Phesgo, Giredestrant, Docetaxel)

Recruiting
  • Locally Advanced or Metastatic Breast Cancer
  • Phesgo
  • +5 more
  • Los Angeles, California
  • +21 more
Jul 25, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • PHESGO
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

Early-stage Breast Cancer Trial in Heidelberg (Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib)

Not yet recruiting
  • Early-stage Breast Cancer
  • Atezolizumab 1200 mg in 20 ML Injection
  • +5 more
  • Heidelberg, Baden-Wuerttemberg, Germany
    National Center for Tumor Diseases
Sep 13, 2022

HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)

Not yet recruiting
  • HER2-positive Breast Cancer
  • (no location specified)
Mar 23, 2022

Advanced Cancer, Solid Tumor Trial in Helsinki, Kuopio, Tampere (Alectinib, Cobimetinib, Vismodegib)

Recruiting
  • Advanced Cancer
  • Solid Tumor
  • Helsinki, Uusimaa, Finland
  • +2 more
Jun 8, 2022

Healthy Male Subjects Trial in Auckland, Christchurch (Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC),

Recruiting
  • Healthy Male Subjects
  • Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
  • +2 more
  • Adelaide, South Australia, Australia
  • +3 more
Feb 1, 2023

Advanced Solid Tumors, HER2-positive Breast Cancer Trial in United States (ZN-A-1041 50mg BID, ZN-A-1041 100mg BID, ZN-A-1041

Recruiting
  • Advanced Solid Tumors
  • HER2-positive Breast Cancer
  • ZN-A-1041 50mg BID
  • +12 more
  • Tucson, Arizona
  • +6 more
Nov 16, 2022

Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Scottsdale, Jacksonville, Rochester

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • Stage IVB Prostate Cancer AJCC v8
  • Biopsy
  • +7 more
  • Scottsdale, Arizona
  • +2 more
Feb 15, 2023

Cancer Metastatic Trial in Norway (Atezolizumab)

Recruiting
  • Cancer Metastatic
  • Bergen, Norway
  • +16 more
Oct 24, 2022

HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer Trial in United States (Pertuzumab+TRASTUZUMAB,

Recruiting
  • HER2-positive Breast Cancer
  • +5 more
  • Pertuzumab+TRASTUZUMAB
  • ADJUVANT ENDOCRINE THERAPY
  • Stamford, Connecticut
  • +21 more
Dec 12, 2022

HER2-positive Early Breast Cancer Trial in China (drug, procedure, radiation)

Active, not recruiting
  • HER2-positive Early Breast Cancer
  • Pertuzumab IV
  • +8 more
  • Beijing, China
  • +17 more
Nov 21, 2022

Metastatic Breast Cancer With a Isolated Brain Progression Trial in France (Tucatinib, Pertuzumab, Trastuzumab)

Recruiting
  • Metastatic Breast Cancer With a Isolated Brain Progression
  • Angers, France
  • +33 more
Aug 10, 2022

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer Trial in Worldwide (Giredestrant, Abemaciclib,

Recruiting
  • Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
  • Duarte, California
  • +27 more
Jan 31, 2023

Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer Trial in Canada, Mexico, Spain (drug, procedure,

Recruiting
  • Early Breast Cancer
  • +2 more
  • Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
  • +6 more
  • Buenos Aires, Argentina
  • +29 more
Jan 31, 2023

Early Breast Cancer Trial in Worldwide (Trastuzumab and Pertuzumab (FDC SC) and T-DM1)

Recruiting
  • Early Breast Cancer
  • Trastuzumab and Pertuzumab (FDC SC) and T-DM1
  • Pleven, Bulgaria
  • +55 more
Jan 18, 2023

HER2-Positive Early Breast Cancer Trial in Worldwide (Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous

Active, not recruiting
Has Results
  • HER2-Positive Early Breast Cancer
  • Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
  • +2 more
  • Lakewood, Colorado
  • +39 more
Apr 4, 2022

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in United States (Crizotinib, Palbociclib, Sunitinib)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • Birmingham, Alabama
  • +125 more
Nov 21, 2022

Advanced Unresectable or Metastatic Solid Malignancy Trial in United States (Entrectinib, Inavolisib, Alectinib)

Recruiting
  • Advanced Unresectable or Metastatic Solid Malignancy
  • Birmingham, Alabama
  • +50 more
Aug 10, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +14 more
  • Biopsy
  • +25 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2022

HER2 Positive Breast Cancer Trial in Worldwide (Tucatinib, Trastuzumab, Pertuzumab)

Recruiting
  • HER2 Positive Breast Cancer
  • Phoenix, Arizona
  • +143 more
Jan 20, 2023